The Discounted Cash Flow (DCF) valuation of Provectus Biopharmaceuticals Inc (PVCT) is (0.32) USD. With the latest stock price at 0.08 USD, the upside of Provectus Biopharmaceuticals Inc based on DCF is -484.4%.
Based on the latest price of 0.08 USD and our DCF valuation, Provectus Biopharmaceuticals Inc (PVCT) is a sell. selling PVCT stocks now will result in a potential gain of 484.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.6% - 7.3% | 6.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (1.30) - (0.19) | (0.32) |
| Upside | -1659.0% - -331.2% | -484.4% |